US3980778A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-inflammatory steroid
Assignee: Pharmacia and Upjohn Co
•
Filing: 1975-05-20
•
Granted: 1976-09-14
•
Expires: 1995-05-20
Abstract
Abstract The disclosure covers the preparation of the compound, 6 alpha ,9 alpha -difluoro-11 beta ,17,21-trihydroxy-16 beta -methylpregna-1,4-diene-3,20-dione 17 alpha ,21-diacetate, (1) and methods and formulations for its anti-inflammatory use topically, orally and parenterally.
Inventors
- 👤 Donald E. Ayer
- 👤 Carl A. Schlagel
- 👤 Gordon L. Flynn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 14:10
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/18; A61K8/30; A61K8/63; A61K8/60; A61K8/602; A61Q; A61Q17/00; A61Q17/04; C; C07; C07J; C07J5/00; C07J5/0046; C07J5/0061; C07J5/0069; C07J5/0076
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
4 words
The chemical compound 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione.
Claim 2
Dependent Claim
4 words
The chemical compound 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione.
Claim 3
Dependent Claim
35 words
A therapeutic composition for topical or local application for treatment of inflammation of skin or mucous membrane comprising from about 0.001% w/w to about 1.0% w/w of 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate in association with a pharmaceutical carrier.
Claim 4
Dependent Claim
35 words
A therapeutic composition for topical or local application for treatment of inflammation of skin or mucous membrane comprising from about 0.001% w/w to about 1.0% w/w of 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate in association with a pharmaceutical carrier.
Claim 5
Independent Claim
35 words
A method for the treatment of inflammation of skin or mucous membrane comprising topical or local application of from about 0.001% w/w to about 1.0% w/w of 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate in association with a pharmaceutical carrier.
Claim 6
Independent Claim
35 words
A method for the treatment of inflammation of skin or mucous membrane comprising topical or local application of from about 0.001% w/w to about 1.0% w/w of 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate in association with a pharmaceutical carrier.
Claim 7
Dependent Claim
23 words
A therapeutic composition comprising, in unit dosage form, from about 0.1 to 25 mg. of 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate in association with a pharmaceutical carrier.
Claim 8
Dependent Claim
23 words
A therapeutic composition comprising, in unit dosage form, from about 0.1 to 25 mg. of 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate in association with a pharmaceutical carrier.
Claim 9
Dependent Claim
36 words
The composition of claim 4 suitable for parenteral administration wherein said pharmaceutical carrier is a sterile vehicle and said compound is present in a concentration of from about 0.01 to about 10% w/v of the composition.
Claim 10
Independent Claim
26 words
A method for treating inflammatory conditions systemically which comprises administering from about 0.1 to about 25 mg. of 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methyl-pregna-1,4-diene-3,20-dione 17,21-diacetate in association with a pharmaceutical carrier.
Claim 11
Independent Claim
26 words
A method for treating inflammatory conditions systemically which comprises administering from about 0.1 to about 25 mg. of 6α,9α-difluoro-11β,17α,21-trihydroxy-16β-methyl-pregna-1,4-diene-3,20-dione 17,21-diacetate in association with a pharmaceutical carrier.
Claim 12
Dependent Claim
19 words
The therapeutic composition as claimed in claim 2 comprising, in addition, a topically effective amount of an antibacterial agent.
Claim 13
Dependent Claim
19 words
The therapeutic composition as claimed in claim 2 comprising, in addition, a therapeutically effective amount of an antifungal agent.
Claim 14
Dependent Claim
13 words
The composition of claim 7 in which the antibacterial agent is neomycin sulfate.
Claim 15
Dependent Claim
28 words
The therapeutic composition as claimed in claim 2 comprising, in addition, a topically effective amount of an antibacterial agent and a topically effective amount of an antifungal agent.
Claim 16
Dependent Claim
12 words
The composition of claim 8 in which the antifungal agent is chloroxine.
Claim 17
Dependent Claim
19 words
The composition of claim 10 in which the antibacterial agent is neomycin sulfate and the antifungal agent is chloroxine.
References Cited (Backward Citations)
US3557158A
Cited
US3691214A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-09-14 | 1980-03-15 | 1980-09-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-09-14 | 1984-03-15 | 1984-09-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-09-14 | 1988-03-15 | 1988-09-14 | $7700.00 | Window Closed / Lapsed |